ClinicalTrials.gg
CompletedNCT06085482Updated May 27, 2026Results posted

A Phase I Study of LY3502970 in Healthy Participants

A Phase 1 interventional study of LY3502970 and [14C]-LY3502970 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
21 Years to 70 Years
Sex
All
01

Study summary

The main purpose of this study is to evaluate how much of the study drug (LY3502970) and the radioactive substance 14C incorporated LY3502970 gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study will last up to approximately 9 weeks for each participant.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy as determined by medical evaluation
  • Participants with body weight of 45 kilograms (kg) or more and within the range 18.5 to 35.0 kilograms per meter squared (kg/m²), inclusive
  • Males who agree to use highly effective or effective methods of and women not of may participate in this study

Exclusion criteria

Exclusion Criteria:

  • Participants who have known allergies to LY3502970, related compounds, or any components of the formulation
  • Women who are lactating and women of child bearing potential () are excluded from the study
  • Participants who regularly use known drugs of abuse or show positive findings on drug screen
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    LY3502970 + [14C]-LY3502970

    Participants received a single oral dose of 1 milligram (mg) LY3502970 followed six hours later by an intravenous (IV) dose of approximately 21 microgram (μg) of LY3502970 radiolabeled with carbon-14 (\[14C\]-LY3502970) containing approximately 800 nanocurie (nCi) radioactivity.

    Drug: LY3502970 · Drug: [14C]-LY3502970

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Absolute Bioavailability of LY3502970

    Absolute bioavailability of LY3502970, expressed in percentage, was estimated using the AUC(0-∞) values from each individual participant based on IV dosed \[14C\]-LY3502970 compared to oral dosed LY3502970, using formula: \[AUC0-∞(oral) x Dose (IV) divided by AUC0-∞(IV) x Dose (oral)\] x100. The sampling time points from pre-oral dose through 186 hours post-IV dose were used to assess this outcome.

    Time frame: Pre-oral dose, 0.5, 1, 2, 4, 6, 6.5, 7, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120 hours post-oral dose; 0 (immediately after IV dosing), 2, 5, 10, 15 minutes and 0.5, 1, 2, 4, 6, 10, 18, 30, 42, 66, 90, 114, 138, 162, 186 hours post-IV dose.

Secondary outcomes

  1. PK: Area Under the Curve Concentration Versus Time Curve From Zero to Infinity (AUC [0-∞]) of Total Radioactivity in Plasma

    PK: AUC \[0-∞\] of Total Radioactivity in Plasma.

    Time frame: 0 (immediately after IV dosing), 2, 5, 10, 15 minutes and 0.5, 1, 2, 4, 6, 10, 18, 30, 42, 66, 90, 114, 138 hours post-IV dose

  2. PK: AUC [0-∞] of [14C]-LY3502970 in Plasma

    PK: AUC \[0-∞\] of \[14C\]-LY3502970 in Plasma.

    Time frame: 0 (immediately after IV dosing), 2, 5, 10, 15 minutes and 0.5, 1, 2, 4, 6, 10, 18, 30, 42, 66, 90, 114, 138, 162, 186 hours post-IV dose

  3. PK: AUC [0-∞] of LY3502970 in Plasma

    PK: AUC \[0-∞\] of LY3502970 in Plasma.

    Time frame: Pre-oral dose, 0.5, 1, 2, 4, 6, 6.5, 7, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120 hours post-oral dose

  4. PK: Maximum Concentration (Cmax) of Total Radioactivity in Plasma

    PK: Cmax of Total Radioactivity in Plasma.

    Time frame: 0 (immediately after IV dosing), 2, 5, 10, 15 minutes and 0.5, 1, 2, 4, 6, 10, 18, 30, 42, 66, 90, 114, 138 hours post-IV dose

  5. PK: Cmax of [14C]-LY3502970 in Plasma

    PK: Cmax of \[14C\]-LY3502970 in Plasma.

    Time frame: 0 (immediately after IV dosing), 2, 5, 10, 15 minutes and 0.5, 1, 2, 4, 6, 10, 18, 30, 42, 66, 90, 114, 138, 162, 186 hours post-IV dose

  6. PK: Cmax of LY3502970 in Plasma

    PK: Cmax of LY3502970 in Plasma.

    Time frame: Pre-oral dose, 0.5, 1, 2, 4, 6, 6.5, 7, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120 hours post-oral dose

07

Results

Posted May 27, 2026

Participant flow

Participant flow — Overall Study
MilestoneLY3502970 + [14C]-LY3502970
Started10
Received ly350297010
Received [14c]-ly350297010
Completed9
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryPharmacokinetics (PK): Absolute Bioavailability of LY3502970

Absolute bioavailability of LY3502970, expressed in percentage, was estimated using the AUC(0-∞) values from each individual participant based on IV dosed \[14C\]-LY3502970 compared to oral dosed LY3502970, using formula: \[AUC0-∞(oral) x Dose (IV) divided by AUC0-∞(IV) x Dose (oral)\] x100. The sampling time points from pre-oral dose through 186 hours post-IV dose were used to assess this outcome.

Time frame:
Pre-oral dose, 0.5, 1, 2, 4, 6, 6.5, 7, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120 hours post-oral dose; 0 (immediately after IV dosing), 2, 5, 10, 15 minutes and 0.5, 1, 2, 4, 6, 10, 18, 30, 42, 66, 90, 114, 138, 162, 186 hours post-IV dose.
Reported as:
Geometric mean · Percentage
Pharmacokinetics (PK): Absolute Bioavailability of LY3502970
PercentageLY3502970 + [14C]-LY3502970
Pharmacokinetics (PK): Absolute Bioavailability of LY350297077 ± 27
SecondaryPK: Area Under the Curve Concentration Versus Time Curve From Zero to Infinity (AUC [0-∞]) of Total Radioactivity in Plasma

PK: AUC \[0-∞\] of Total Radioactivity in Plasma.

Time frame:
0 (immediately after IV dosing), 2, 5, 10, 15 minutes and 0.5, 1, 2, 4, 6, 10, 18, 30, 42, 66, 90, 114, 138 hours post-IV dose
Reported as:
Geometric mean · nanogram equivalent*hour per milliliter
PK: Area Under the Curve Concentration Versus Time Curve From Zero to Infinity (AUC [0-∞]) of Total Radioactivity in Plasma
nanogram equivalent*hour per milliliterLY3502970 + [14C]-LY3502970
PK: Area Under the Curve Concentration Versus Time Curve From Zero to Infinity (AUC [0-∞]) of Total Radioactivity in Plasma3.71 ± 29
SecondaryPK: AUC [0-∞] of [14C]-LY3502970 in Plasma

PK: AUC \[0-∞\] of \[14C\]-LY3502970 in Plasma.

Time frame:
0 (immediately after IV dosing), 2, 5, 10, 15 minutes and 0.5, 1, 2, 4, 6, 10, 18, 30, 42, 66, 90, 114, 138, 162, 186 hours post-IV dose
Reported as:
Geometric mean · nanogram equivalent*hour per milliliter
PK: AUC [0-∞] of [14C]-LY3502970 in Plasma
nanogram equivalent*hour per milliliterLY3502970 + [14C]-LY3502970
PK: AUC [0-∞] of [14C]-LY3502970 in Plasma2.91 ± 19
SecondaryPK: AUC [0-∞] of LY3502970 in Plasma

PK: AUC \[0-∞\] of LY3502970 in Plasma.

Time frame:
Pre-oral dose, 0.5, 1, 2, 4, 6, 6.5, 7, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120 hours post-oral dose
Reported as:
Geometric mean · nanogram*hour per milliliter
PK: AUC [0-∞] of LY3502970 in Plasma
nanogram*hour per milliliterLY3502970 + [14C]-LY3502970
PK: AUC [0-∞] of LY3502970 in Plasma108 ± 35
SecondaryPK: Maximum Concentration (Cmax) of Total Radioactivity in Plasma

PK: Cmax of Total Radioactivity in Plasma.

Time frame:
0 (immediately after IV dosing), 2, 5, 10, 15 minutes and 0.5, 1, 2, 4, 6, 10, 18, 30, 42, 66, 90, 114, 138 hours post-IV dose
Reported as:
Geometric mean · nanogram equivalent per milliliter
PK: Maximum Concentration (Cmax) of Total Radioactivity in Plasma
nanogram equivalent per milliliterLY3502970 + [14C]-LY3502970
PK: Maximum Concentration (Cmax) of Total Radioactivity in Plasma2.10 ± 59
SecondaryPK: Cmax of [14C]-LY3502970 in Plasma

PK: Cmax of \[14C\]-LY3502970 in Plasma.

Time frame:
0 (immediately after IV dosing), 2, 5, 10, 15 minutes and 0.5, 1, 2, 4, 6, 10, 18, 30, 42, 66, 90, 114, 138, 162, 186 hours post-IV dose
Reported as:
Geometric mean · nanogram equivalent per milliliter
PK: Cmax of [14C]-LY3502970 in Plasma
nanogram equivalent per milliliterLY3502970 + [14C]-LY3502970
PK: Cmax of [14C]-LY3502970 in Plasma2.08 ± 53
SecondaryPK: Cmax of LY3502970 in Plasma

PK: Cmax of LY3502970 in Plasma.

Time frame:
Pre-oral dose, 0.5, 1, 2, 4, 6, 6.5, 7, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120 hours post-oral dose
Reported as:
Geometric mean · nanogram per milliliter
PK: Cmax of LY3502970 in Plasma
nanogram per milliliterLY3502970 + [14C]-LY3502970
PK: Cmax of LY3502970 in Plasma5.43 ± 42

Adverse events

Collected over Baseline through end of the follow-up (Up to Day 19). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY3502970 + [14C]-LY35029700/10 (0%)0/10 (0%)2/10 (20%)
Most frequent other events
Most frequent other events
EventLY3502970 + [14C]-LY3502970
Vessel puncture site painGeneral disorders1/10
COVID-19Infections and infestations1/10
HeadacheNervous system disorders1/10

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)LY3502970 + [14C]-LY3502970
Mean52.4 ± 13
Sex: Female, Male
Sex: Female, Male(Participants)LY3502970 + [14C]-LY3502970
Female5
Male5
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LY3502970 + [14C]-LY3502970
Hispanic or Latino0
Not Hispanic or Latino10
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LY3502970 + [14C]-LY3502970
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American3
White7
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Covance Clinical Research Inc
    Madison, Wisconsin 53704, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Jan 2024, 2 months.

Results were first posted in May 2026, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2023
First posted
Oct 17, 2023
StartActual
Oct 19, 2023
Primary completionActual
Jan 5, 2024
CompletionActual
Jan 5, 2024
Results first posted
May 27, 2026
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06085482
Responsible party
Sponsor
First posted
Oct 17, 2023
Start date
Oct 19, 2023
Primary completion
Jan 5, 2024
Completion
Jan 5, 2024
Results posted
May 27, 2026
Last update
May 27, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion